Principal Financial Group Inc Esperion Therapeutics, Inc. Transaction History
Principal Financial Group Inc
- $176 Billion
- Q2 2025
A detailed history of Principal Financial Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 393,290 shares of ESPR stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
393,290
Previous 13,256
2866.88%
Holding current value
$1.12 Million
Previous $19,000
1926.32%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding ESPR
# of Institutions
185Shares Held
109MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$39.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$33.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$29.4 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$28.3 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$19 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $189M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...